Chroma Medicine

01 / WHAT IT BUILT

What the company did

Chroma Medicine was a Boston-area biotechnology company developing genomic medicines based on epigenetic editing — controlling gene expression without altering the underlying DNA, eliminating the risk of activating DNA pathways and possible genomic rearrangement associated with conventional gene editing. Having raised about $260 million, it combined its 'best-in-class' epigenetic editing technology with a pipeline of genetic-medicine programs. On December 11, 2024, Chroma Medicine merged with Nvelop Therapeutics to form nChroma Bio, uniting epigenetic editing with next-generation in vivo non-viral delivery to unlock the full potential of genetic medicines; the combined company simultaneously raised $75 million. nChroma's lead program, CRMA-1001, is a liver-targeted epigenetic editing therapy aimed at functional cures for chronic hepatitis B and hepatitis D.

03 / EVENT HISTORY

Events in the structured record

1. 2021
   Launch

   Launched as a genomic-medicines company built on epigenetic editing — controlling gene expression without altering DNA; raised about $260 million in total across its independent life.

2. 2024
   Merger into nChroma Bio

   On December 11, 2024, Chroma Medicine and Nvelop Therapeutics merged to form nChroma Bio, combining epigenetic editing with in vivo non-viral delivery; the combined company raised $75 million, led by Cormorant Asset Management, ARCH, Atlas and Newpath, with Jeff Walsh as CEO and Jeff Marrazzo as chairman; lead program CRMA-1001 targets chronic hepatitis B and D.